Comparison of Efficacy, Safety and Cost of Therapy with Oral Ferrous Ascorbate and Ferrous Sulphate in Patients with Iron Deficiency Anemia
Journal Title: Journal of Drug Discovery and Therapeutics - Year 2014, Vol 2, Issue 8
Abstract
Objective: To compare the efficacy and safety of oral ferrous ascorbate and ferrous sulphate in patients with iron deficiency anemiaMethods: An observational, prospective study in patients of anemia in chronic kidney disease (CKD) and pregnancy receiving oral ferrous ascorbate and ferrous sulfate respectively were included. Demographic details, clinical history, baseline hemoglobin, anemia indices data were recorded in a case record form. The patients were followed up monthly for 12 weeks and observed for clinical and hematological improvement and adverse drug reactions (ADRs). The data was analyzed using paired t-test, unpaired t-test and Fisher`s exact test.Results: Out of 148 anemic patients, 62 CKD patients received ferrous ascorbate and 86 pregnant patients treated with ferrous sulfate. Ferrous ascorbate and ferrous sulphate have significantly (P<0.0001) improved mean hemoglobin and anemia indices at the end of study, however, mean increase in hemoglobin was more and significant (P<0.000) with ferrous ascorbate (3.45 g/dL) as compared to ferrous sulfate (3.3 g/dL). Mean increase in MCV and MCHC were comparable in both ferrous ascorbate and ferrous sulfate treated patients, however, mean increase in MCH was significantly (P <0.005) with ferrous sulfate (4.7 pg/cell) treated patients as compared to ferrous ascorbate (3.15 pg/cell). ADRs were more in patients treated with ferrous sulfate (86%) than ferrous ascorbate (71%). Cost of therapy incurred to patient treated with ferrous ascorbate (Rs. 1269.6) was three time more as compared to ferrous sulfate (Rs. 409.7).Conclusion: Ferrous ascorbate and ferrous sulfate, both were effective and safe in treating iron deficiency anemia in patients with CKD and pregnancy respectively. However, ferrous ascorbate increased hemoglobin more, with better tolerated by patients. Unfortunately, cost of therapy with ferrous ascorbate was high as compared to ferrous sulfate.
Authors and Affiliations
Panchal Pavan J| MD Pharmacology, Department of Pharmacology, B. J. Medical College, Ahmedabad-380016, India, Desai Mira K| MD Pharmacology, Department of Pharmacology, B. J. Medical College, Ahmedabad-380016, India
Keywords
Related Articles
- EP ID EP1502
- DOI -
- Views 574
- Downloads 25
Formulation & evaluation of voriconazole ointment for topical delivery
The studies were conducted with an object to develop a desired ointment for treatment of fungal infection like eczema itching, purities’. Main objective of this study is to formulate the ointment with different ointment...
BARBTURATES FOR TREATMENT OF EPILEPSY
Barbiturates in the brain. Barbiturates have their primary actions on the GABAA receptor, but they also interact with glutamate receptors and voltage-gated ion channels. Because of the impressive recent advances in molec...
CHANGING TREND OF ANTIBIOTIC SUSCEPTIBILITY PATTERN OF COMMON GRAM NEGATIVE BACILLI ISOLATED FROM MEDICAL INTENSIVE CARE UNIT OF TERTIARY CARE HOSPITAL AHMEDABAD, GUJARAT, INDIA
Introduction: Resistance among Gram-negative bacilli antimicrobial remains a significant problem for patients in the intensive care unit (ICU). Multi-resistant gram-negative bacilli are important pathogens in ICUs, caus...
FORMULATION AND EVALUATION OF COLON TARGETED DELAYED RELEASE MICROSPHERIC CAPSULES OF ALBENDAZOLE
The aim of the present work was to prepare and evaluate the colon targeted delayed release microspheric capsules of albendazole. The preparation of albendazole microspheres by ionic gelation method avoids the usage of to...
Formulation and evaluation of tramadol and diclofenac sodium multimodal sustain release tablet dosage form
Pain is treated using the unimodal pain management which are based on either central analgesic drug mechanism or other drug like nsaid. These drugs control the pain by central nervous system or peripheral nervous system....